Abstract:A machine learning‐derived LCDS using peripheral blood transcriptomics enables early detection of lung cancer with high accuracy. Lower LCDS correlates with enhanced antitumor immunity, while higher LCDS associates with protumorigenic pathway activation. LCDS shows potential as a noninvasive biomarker for lung cancer screening and prognosis. Lung cancer continues to be the leading cause of cancer‐related mortality worldwide. Early detection and a comprehensive understanding of tumor‐immune interactions are crucial for improving patient outcomes. This study aimed to develop a novel biomarker panel utilizing peripheral blood transcriptomics and machine learning algorithms for early lung cancer diagnosis, while simultaneously providing insights into tumor‐immune crosstalk mechanisms. Leveraging a training cohort (GSE135304), we employed multiple machine learning algorithms to formulate a Lung Cancer Diagnostic Score (LCDS) based on peripheral blood transcriptomic features. The LCDS model's performance was evaluated using the area under the receiver operating characteristic (ROC) curve (AUC) in multiple validation cohorts (GSE42834, GSE157086, and an in‐house dataset). Peripheral blood samples were obtained from 20 lung cancer patients and 10 healthy control subjects, representing an in‐house cohort recruited at the Sixth People's Hospital of Chengdu. We employed advanced bioinformatics techniques to explore tumor‐immune interactions through comprehensive immune infiltration and pathway enrichment analyses. Initial screening identified 844 differentially expressed genes, which were subsequently refined to 87 genes using the Boruta feature selection algorithm. The random forest (RF) algorithm demonstrated the highest accuracy in constructing the LCDS model, yielding a mean AUC of 0.938. Lower LCDS values were significantly associated with elevated immune scores and increased CD4+ and CD8+ T‐cell infiltration, indicative of enhanced antitumor‐immune responses. Higher LCDS scores correlated with activation of hypoxia, peroxisome proliferator‐activated receptor (PPAR), and Toll‐like receptor (TLR) signaling pathways, as well as reduced DNA damage repair pathway scores. Our study presents a novel, machine learning‐derived peripheral blood transcriptomic biomarker panel with potential applications in early lung cancer diagnosis. The LCDS model not only demonstrates high accuracy in distinguishing lung cancer patients from healthy individuals but also offers valuable insights into tumor‐immune interactions and underlying cancer biology. This approach may facilitate early lung cancer detection and contribute to a deeper understanding of the molecular and cellular mechanisms underlying tumor‐immune crosstalk. Furthermore, our findings on the relationship between LCDS and immune infiltration patterns may have implications for future research on therapeutic strategies targeting the immune system in lung cancer.

Machine learning-based proteogenomic data modeling identifies circulating plasma biomarkers for early detection of lung cancer

Plasma protein biomarkers for early prediction of lung cancer

Machine Learning Identifies Immune-Based Biomarkers That Predict Efficacy of Anti-Angiogenesis-based Therapies in Advanced Lung Cancer

A Peripheral Blood Transcriptomic Biomarker Panel Identified by Multiple Machine Learning Algorithms Enables Early Diagnosis and Prognosis Prediction in Lung Cancer

Machine learning‐derived peripheral blood transcriptomic biomarkers for early lung cancer diagnosis: Unveiling tumor‐immune interaction mechanisms

Multiplex plasma protein assays as a diagnostic tool for lung cancer

Integrated plasma and exosome long noncoding RNA profiling is promising for diagnosing non-small cell lung cancer

Integrated Models of Blood Protein and Metabolite Enhance the Diagnostic Accuracy for Non-Small Cell Lung Cancer

Exploration of potential novel drug targets and biomarkers for small cell lung cancer by plasma proteome screening

Early lung cancer diagnostic biomarker discovery by machine learning methods

Circulating microbiome DNA as biomarkers for early diagnosis and recurrence of lung cancer

Plasma proteometabolome in lung cancer: exploring biomarkers through bidirectional Mendelian randomization and colocalization analysis

Machine learning approach to predict blood-secretory proteins and potential biomarkers for liver cancer using omics data

Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling

Abstract 784: Proteome-wide mendelian randomization identifies causal association between plasma proteins and lung cancer

Identification of Exosome Protein Panels As Predictive Biomarkers for Non-Small Cell Lung Cancer

Accurate Early Detection and EGFR Mutation Status Prediction of Lung Cancer Using Plasma Cfdna Coverage Patterns: A Proof-of-Concept Study

Quantitative proteomics identified circulating biomarkers in lung adenocarcinoma diagnosis

Clinical Verification of Plasma Messenger RNA As Novel Noninvasive Biomarker Identified Through Bioinformatics Analysis for Lung Cancer.

Predicting the risk of lung cancer using machine learning: A large study based on UK Biobank

Machine Learning for Early Discrimination Between Lung Cancer and Benign Nodules Using Routine Clinical and Laboratory Data